keyword
MENU ▼
Read by QxMD icon Read
search

Liposarcoma treatment

keyword
https://www.readbyqxmd.com/read/28637688/fus-ddit3-fusion-protein-driven-igf-ir-signaling-is-a-therapeutic-target-in-myxoid-liposarcoma
#1
Marcel Trautmann, Jasmin Menzel, Christian Bertling, Magdalene Cyra, Ilka Isfort, Konrad Steinestel, Sandra Elges, Inga Grünewald, Bianca Altvater, Claudia Rossig, Stefan Fröhling, Susanne Hafner, Thomas Simmet, Pierre Åman, Eva Wardelmann, Sebastian Huss, Wolfgang Hartmann
Purpose: Myxoid liposarcoma is an aggressive disease with particular propensity to develop hematogenic metastases. Over 90% of myxoid liposarcoma are characterized by a reciprocal t(12;16)(q13;p11) translocation. The resulting chimeric FUS-DDIT3 fusion protein plays a crucial role in myxoid liposarcoma pathogenesis; however, its specific impact on oncogenic signaling pathways remains to be substantiated. We here investigate the functional role of FUS‑DDIT3 in IGF-IR/PI3K/Akt signaling driving myxoid liposarcoma pathogenesis...
June 21, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28629371/combined-targeting-of-mdm2-and-cdk4-is-synergistic-in-dedifferentiated-liposarcomas
#2
Audrey Laroche-Clary, Vanessa Chaire, Marie-Paule Algeo, Marie-Alix Derieppe, François L Loarer, Antoine Italiano
PURPOSE: MDM2 and CDK4 are frequently co-amplified in well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). We aimed to determine whether combined MDM2/CDK4 targeting is associated with higher antitumour activity than a single agent in preclinical models of DDLPS. EXPERIMENTAL DESIGN: DDLPS cells were exposed to RG7388 (MDM2 antagonist) and palbociclib (CDK4 inhibitor), and apoptosis and signalling/survival pathway perturbations were monitored by flow cytometry and Western blotting...
June 19, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28621163/eribulin-in-advanced-liposarcoma-and-leiomyosarcoma
#3
Elisabetta Setola, Jonathan Noujaim, Charlotte Benson, Sant Chawla, Emanuela Palmerini, Robin L Jones
The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial...
June 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28607580/neoadjuvant-chemotherapy-in-soft-tissue-sarcomas-latest-evidence-and-clinical-implications
#4
REVIEW
Sandro Pasquali, Alessandro Gronchi
Soft tissue sarcomas are a rare and multifaceted group of solid tumours. Neoadjuvant chemotherapy is increasingly used to limit loss of function after wide surgical excision with the ultimate aim of improving patient survival. Recently, advances in the identification of effective treatment strategies and improvements in patient risk stratification have been reached. A randomized trial demonstrated that neoadjuvant epirubicin and ifosfamide improves survival of patients affected by five high-risk soft tissue sarcoma histologies of trunk and extremities, including undifferentiated pleomorphic sarcoma, myxoid liposarcoma, synovial sarcoma, malignant peripheral nerve sheath tumours, and leiomyosarcoma...
June 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28601782/neuropraxia-following-resection-of-a-retroperitoneal-liposarcoma
#5
Stevenson Tsiao, Nail Aydin, Subhasis Misra
BACKGROUND: This is a unique case of neuropraxia of femoral nerve seen after resection of retroperitoneal liposarcoma which has not been reported before in the literature. INTRODUCTION: Neuropraxia, a transient paralysis due to blockage of nerve conduction, commonly associated with athletes and orthopedic procedures, has not been previously reported as a complication following resection of retroperitoneal sarcoma. CASE: This is an 81-year-old female who, on CT for evaluation of her atherosclerosis, was found to have an incidental right-sided retroperitoneal mass extending from the right renal capsule inferiorly through the inguinal canal...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28601416/statistics-of-soft-tissue-sarcoma-in-japan-report-from-the-bone-and-soft-tissue-tumor-registry-in-japan
#6
Koichi Ogura, Takahiro Higashi, Akira Kawai
BACKGROUND: No previous reports to date have characterized the national profiles of soft-tissue sarcomas (STSs). In the present study, we reviewed current practice for STSs in Japan using data from a nationwide organ-specific cancer registry for bone and soft-tissue tumors in Japan, the Bone and Soft Tissue Tumor (BSTT) Registry. METHODS: In the registry, we identified 8228 patients with STSs during the period 2006-2012, and extracted data on patient demographics, treatment, and outcome at the last follow-up for each patient...
June 7, 2017: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://www.readbyqxmd.com/read/28591457/cutaneous-sarcomas
#7
Judith Kohlmeyer, Susanne Annette Steimle-Grauer, Rüdiger Hein
Cutaneous sarcomas comprise a heterogeneous group of mesenchymal spindle cell tumors of the dermis and subcutis, one of the best-known entities being dermatofibrosarcoma protuberans. Other sarcomas addressed in this review include atypical fibroxanthoma, cutaneous undifferentiated pleomorphic sarcoma, leiomyosarcoma, liposarcoma, and angiosarcoma. With the exception of dermatofibrosarcoma protuberans, which has its peak incidence in middle-aged adults, cutaneous sarcomas usually occur in elderly individuals starting in the sixth or seventh decade of life...
June 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28591446/kutane-sarkome
#8
Judith Kohlmeyer, Susanne Annette Steimle-Grauer, Rüdiger Hein
Cutaneous sarcomas comprise a heterogeneous group of mesenchymal spindle cell tumors of the dermis and subcutis, one of the best-known entities being dermatofibrosarcoma protuberans. Other sarcomas addressed in this review include a typical fibroxanthoma, cutaneous undifferentiated pleomorphic sarcoma, leiomyosarcoma, liposarcoma, and angiosarcoma. With the exception of dermatofibrosarcoma protuberans, which has its peak incidence in middle-aged adults, cutaneous sarcomas usually occur in elderly individuals starting in the sixth or seventh decade of life...
June 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28588009/exosome-derived-mir-25-3p-and-mir-92a-3p-stimulate-liposarcoma-progression
#9
Lucia Casadei, Federica Calore, Chad J Creighton, Michele Guescini, Kara Batte, O Hans Iwenofu, Abeba Zewdu, Danielle Braggio, Kate Lynn Bill, Paolo Fadda, Francesca Lovat, Gonzalo Lopez, Pierluigi Gasparini, James L Chen, Raleigh D Kladney, Gustavo Leone, Dina Lev, Carlo M Croce, Raphael E Pollock
Despite the development of combined modality treatments against liposarcoma (LPS) in recent years, a significant proportion of patients respond only modestly to such approaches, possibly contributing to local or distant recurrence. Early detection of recurrent or metastatic disease could improve patient prognosis by triggering earlier clinical intervention. However, useful biomarkers for such purposes are lacking. Using both patient plasma samples and cell lines, we demonstrate here that miR-25-3p and miR-92a-3p are secreted by LPS cells through extracellular vesicles and may be useful as potential biomarkers of disease...
June 6, 2017: Cancer Research
https://www.readbyqxmd.com/read/28573464/imaging-features-of-mammary-type-myofibroblastoma-of-soft-tissue-a-case-series-with-literature-review
#10
Gokhan Kuyumcu, Brian P Rubin, Carl Winalski
Mammary-type myofibroblastoma (MTM) is a rare, benign neoplasm that is histologically identical to myofibroblastoma of the breast, but occurring in an extramammary site. The masses have been reported in superficial and deep soft tissue sites and visceral locations with the inguinal area and lower extremities are the most common. Most previous reports of MTMs have concentrated on clinical and pathological findings, with very limited information regarding imaging characteristics. Here, we describe three cases of MTM diagnosed at our institution, with a focus on imaging findings...
June 1, 2017: Skeletal Radiology
https://www.readbyqxmd.com/read/28566438/in-vivo-antitumoral-efficacy-of-phac-algp-doxorubicin-an-enzyme-activated-doxorubicin-prodrug-in-patient-derived-soft-tissue-sarcoma-xenograft-models
#11
Jasmien Cornillie, Agnieszka Wozniak, Peter Pokreisz, Andrea Casazza, Lise Vreys, Jasmien Wellens, Ulla Vanleeuw, Yemarshet K Gebreyohannes, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, Patrick Schöffski
Given the very limited efficacy of doxorubicin (doxo) in soft tissue sarcoma, there is a clear need for more active and less toxic treatments for this family of diseases. However, due to the rarity of these malignancies and lack of reliable preclinical models, development of new therapies has lagged behind. <p>We evaluated the efficacy of PhAc-ALGP-doxorubicin (ALGP-doxo), a prodrug metabolized to doxo by peptidases present in tumor cells and/or tumor microenvironment, in a synovial sarcoma (SynSa) and two dedifferentiated liposarcoma (DDLPS) patient-derived xenograft models...
May 31, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28551391/preoperative-vs-postoperative-radiation-therapy-in-localized-soft-tissue-sarcoma-nationwide-patterns-of-care-and-trends-in-utilization
#12
Stanislav Lazarev, Heather McGee, Erin Moshier, Meng Ru, Elizabeth G Demicco, Vishal Gupta
PURPOSE: The timing of perioperative radiation therapy (RT) in the treatment of soft tissue sarcoma (STS) varies among institutions. This study examines patterns of care, trends in utilization, and survival with preoperative versus postoperative RT for primary STS. METHODS AND MATERIALS: Using the National Cancer Data Base, we identified patients with stage I-III STS who underwent definitive surgery with either preoperative or postoperative RT between 2004 and 2012...
April 18, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28534249/trabectedin-and-eribulin-where-do-they-fit-in-the-management-of-soft-tissue-sarcoma
#13
REVIEW
Ravin Ratan, Shreyaskumar R Patel
Trabectedin and eribulin are two agents that have been recently approved for the treatment of specific soft tissue sarcoma subtypes. They have proved to be a much-needed line of additional treatment for patients with these rare tumors, but their activity remains admittedly modest in most cases. Further exploitation of these novel agents is likely to require a more granular understanding of the salient mechanisms of action. For example, if as some studies suggest, eribulin derives its benefit from restructuring of tumor vasculature to improve efficacy of subsequent lines of therapy, then patients may benefit from its use earlier in the treatment pathway...
June 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28533883/-subcutaneous-myxoid-liposarcoma
#14
Asmâa Naim, Nadia Benchekroune, Zineb Bouchbika, Nezha Taoufiq, Hassan Jouhadi, Souha Sahraoui, Abdelatif Benider
Although myxoid liposarcomas (MLS) are the most common type of soft-tissue sarcomas in adults, their primary location in the superficial tissues is rare. So sarcomas are classified as superficial and deep-seated. They are distinct based on their location and their frequency as well as their prognosis which is relatively better in superficial sarcomas. We here report the case of a patient with subcutaneous liposarcoma in the right thigh. The diagnosis was confirmed by histology after clinical symptoms had evolved over 1 year...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28532545/-relapsed-pleomorphic-liposarcoma-with-mediastinal-metastasis-a-case-report-%C3%A2-and-review-of-the-literature
#15
Jinghao Liu, Zuoqing Song, Renwang Liu, Minghui Liu, Dian Ren, Qinghua Zhou, Jun Chen
Metastatic pleomorphic liposarcoma in the mediastinum is rare, and the current treatments are most of the times ineffective. We hereby report a case with relapsed pleomorphic liposarcoma adjacent to the psoas major muscle and with mediastinal metastasis, to discuss the clinical features and treatment strategies of pleomorphic liposarcoma. The patient's clinical history, imaging findings, pathological diagnosis, and multidisciplinary treatments were retrospectively analyzed. A 41-year old female patient was diagnosed with pleomorphic liposarcoma adjacent to the psoas major muscle and mediastinal metastasis...
May 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28528729/pleomorphic-liposarcoma-of-the-head-and-neck-presentation-of-two-cases-and-literature-review
#16
Jay Agarwal, Sameep Kadakia, Abbas Agaimy, Anna Ogadzanov, Azita Khorsandi, Raymond L Chai
BACKGROUND: Pleomorphic liposarcoma (PL) is an exceedingly rare tumor of the head and neck. This aggressive liposarcoma variant portends a poorer prognosis compared to more typical sarcomatous tumors. METHODS: Multi-institutional study including two cases of PL, the first case occurring in the post-auricular region and the second in the cheek with later recurrence within the parotid bed. RESULTS: Both patients were treated surgically with wide local excision...
April 22, 2017: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/28526720/efficacy-of-trabectedin-in-patients-with-advanced-translocation-related-sarcomas-pooled-analysis-of-two-phase-ii-studies
#17
Mitsuru Takahashi, Shunji Takahashi, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Tsukasa Yonemoto, Hideo Morioka, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Masashi Shimura, Akira Kawai
BACKGROUND: Trabectedin is reported as effective, especially against translocation-related sarcomas (TRSs) after failure of or intolerance to standard chemotherapy. We conducted two phase II studies of TRS, confirming high efficacy of 1.2 mg/m(2) trabectedin. The updated data of 66 patients in these studies was integrated to evaluate the efficacy of trabectedin against each histological subtype, and analyze final overall survival (OS). METHODS: Trabectedin was administered on day one of a 21-day cycle...
May 18, 2017: Oncologist
https://www.readbyqxmd.com/read/28509807/treatment-of-retroperitoneal-sarcoma-current-standards-and-new-developments
#18
Winan J van Houdt, Shane Zaidi, Christina Messiou, Khin Thway, Dirk C Strauss, Robin L Jones
PURPOSE OF REVIEW: Retroperitoneal sarcomas are rare tumors and with complex treatment. In this manuscript we give an overview of current standards in treatment of this disease and discuss new developments. RECENT FINDINGS: Surgery with complete resection of the primary tumor is still the only curative modality. The role of preoperative radiotherapy is not clear and is currently being investigated in a clinical trial. Neo-adjuvant chemotherapy is not the standard of care but can be considered occasionally when complete resection is uncertain...
July 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28499583/histotype-tailored-neoadjuvant-chemotherapy-versus-standard-chemotherapy-in-patients-with-high-risk-soft-tissue-sarcomas-isg-sts-1001-an-international-open-label-randomised-controlled-phase-3-multicentre-trial
#19
Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Umberto Basso, Jean-Yves Blay, Oscar Tendero, Robert Diaz Beveridge, Virginia Ferraresi, Iwona Lugowska, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Davide Maria Donati, Elena Palassini, Emanuela Palmerini, Rita De Sanctis, Carlo Morosi, Silvia Stacchiotti, Silvia Bagué, Jean Michelle Coindre, Angelo Paolo Dei Tos, Piero Picci, Paolo Bruzzi, Paolo Giovanni Casali
BACKGROUND: Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue sarcoma of the extremities or trunk wall, and no difference in overall survival benefit between three cycles versus five cycles of the same neoadjuvant regimen. We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy. METHODS: For this international, open-label, randomised, controlled, phase 3, multicentre trial, patients were enrolled from 32 hospitals in Italy, Spain, France, and Poland...
May 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28494349/trabectedin-and-campthotecin-synergistically-eliminate-cancer-stem-cells-in-cell-of-origin-sarcoma-models
#20
Lucia Martinez-Cruzado, Juan Tornin, Aida Rodriguez, Laura Santos, Eva Allonca, Maria Teresa Fernandez-Garcia, Aurora Astudillo, Juana Maria Garcia-Pedrero, Rene Rodriguez
Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and undifferentiated pleomorphic sarcoma (UPS) developed from transformed human mesenchymal stromal/stem cells (MSCs) to evaluate the effect of trabectedin in the cell type responsible for initiating sarcomagenesis and their derived cancer stem cells (CSC) subpopulations. We found that low nanomolar concentrations of trabectedin efficiently inhibited the growth of sarcoma-initiating cells, induced cell cycle arrest, DNA damage and apoptosis...
May 8, 2017: Neoplasia: An International Journal for Oncology Research
keyword
keyword
64164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"